Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Consulting agrmnt
|
|
Enliven Therapeutics, Inc. (IMRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Enliven Therapeutics, Inc. Selected Condensed Consolidated Financial Information Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 15,183 $ 7,937 $ 27,063 $ 14,996 General and administrative 4,951 1,079 9,489 2,698 Total operating expenses 20,134 9,016 36,552 17,694 Loss from operations Other income , net 3,413 127 5,107 136 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares outstanding, basic and diluted 40,961 3,104 29,862 2,991 Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and marketable securities $ 277,865 $ 75,536 Prepaid expenses and other current assets 5,310 2,217 Total current assets 283,175 77,753 Pr..." |
|
| 07/06/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13G
| FMR LLC reports a 10.7% stake in ENLIVEN THERAPEUTICS INC |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/21/2023 |
8-K/A
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/13/2023 |
SC 13G
| Venrock Healthcare Capital Partners III, L.P. reports a 5.4% stake in Enliven Therapeutics, Inc. |
| 03/06/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.6% stake in Enliven Therapeutics, Inc. |
| 03/06/2023 |
SC 13D
| 5AM Ventures VI, L.P. reports a 14.1% stake in Enliven Therapeutics, Inc. |
| 03/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
8-K
| Acquisition/merger/asset purchase announced, Entered into consulting agreement|
Docs:
|
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Contingent Value Rights Agreement between the Company and Rights Agent",
"November 10, 2022",
"February 14, 2020",
"Rahul Ballal Separation Agreement",
"March 15, 2022",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"Contingent Value Rights Agreement between the Company and Rights Agent" |
|
| 02/28/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/28/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/27/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 5.2% stake in ENLIVEN THERAPEUTICS, INC. |
| 02/22/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/22/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.4% stake in IMARA, INC. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.5% stake in Imara Inc. |
| 02/13/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/24/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/23/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/06/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 12/19/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 12/05/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|
|
|